+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rheumatology Therapeutics Market - Global Forecast 2026-2032- Product Image
Rheumatology Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Rheumatology Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011655
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Rheumatology Therapeutics Market is projected to reach USD 37.68 Billion in 2026. It is expected to continue growing at a CAGR of 6.71%, reaching USD 55.88 Billion by 2032.

Rheumatology therapeutics is advancing from symptom control toward precision disease modification across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, vasculitis, gout, and osteoarthritis pain management. The category remains anchored by conventional synthetic disease-modifying antirheumatic drugs, biologics, targeted synthetic DMARDs such as JAK inhibitors, corticosteroids, NSAIDs, analgesics, and supportive care.

The demand base is clinically significant and well documented. The World Health Organization estimates that rheumatoid arthritis affected about 18 million people globally in 2019, while osteoarthritis affected approximately 528 million people. Aging populations, earlier diagnosis, treat-to-target strategies, expanding specialty access, and the growing recognition of autoimmune and musculoskeletal disease burden continue to sustain demand for effective, safe, and reimbursable rheumatology drugs.

Transformative Shifts in Rheumatology Therapeutics

The rheumatology therapeutics landscape is being reshaped by the shift from broad immunosuppression to pathway-selective intervention. TNF inhibitors remain foundational in inflammatory arthritis, while IL-6, IL-17, IL-23, B-cell, T-cell costimulation, complement, interferon, and JAK pathway agents are expanding treatment choices across autoimmune and autoinflammatory diseases.

Biosimilars are transforming pricing, procurement, and access, especially for high-volume biologics used in rheumatoid arthritis, psoriasis-related arthritis, and spondyloarthritis. At the same time, safety surveillance, boxed warnings for some targeted therapies, infection-risk management, and payer-driven step therapy are making real-world evidence, pharmacovigilance, adherence support, and differentiated outcomes essential for commercial success.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing rheumatology therapeutics through trial design, imaging interpretation, patient stratification, drug repurposing, biomarker discovery, and pharmacovigilance. Machine learning can help identify disease activity patterns from electronic health records, claims, laboratory markers, ultrasound, MRI, radiographs, and patient-reported outcomes, supporting more targeted enrollment and outcome measurement.

The cumulative impact is expected to be greatest where AI reduces diagnostic delay, predicts treatment response, detects safety signals, and improves adherence monitoring. However, clinical validation, algorithm transparency, representative datasets, privacy protection, and regulatory-grade evidence remain critical because rheumatic diseases vary by ethnicity, comorbidity burden, disease duration, socioeconomic access, and prior treatment exposure.

Key Regional Insights for Rheumatology Therapeutics

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia expand specialty care, biosimilar adoption, and local clinical development. Japan and Australia have mature regulatory and reimbursement pathways, while China and India provide large patient pools and growing use of targeted therapies, although access remains uneven across urban and rural health systems. In North America, rheumatology therapeutics adoption is supported by specialist density, advanced clinical trial infrastructure, patient advocacy, and active payer management, with treatment decisions increasingly shaped by evidence requirements, prior authorization, and value-based access discussions.

Europe remains a major evidence-generation and biosimilar adoption center, strengthened by centralized and national regulatory processes, health technology assessment frameworks, and guideline-led treat-to-target care. Latin America is improving diagnosis and biologic availability in countries with expanding public and private specialty networks, but affordability and procurement consistency remain key constraints. The Middle East, particularly tertiary-care-focused health systems, is advancing access to biologics and targeted synthetic therapies, while Africa continues to face wider gaps in specialist availability, diagnostics, cold-chain logistics, and reimbursement, making scalable access models essential for long-term rheumatology care.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding through improving hospital networks, public insurance coverage, specialty clinic development, and biosimilar availability, though access differs materially between Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries benefit from investment in tertiary care, national health transformation programs, high biologic uptake in specialist centers, and procurement models that increasingly evaluate long-term outcomes, budget impact, and treatment continuity. The European Union is a global benchmark for biosimilar competition, pharmacovigilance, health technology assessment, and cross-country evidence expectations in rheumatology therapeutics.

BRICS economies combine large autoimmune and musculoskeletal disease burdens with growing domestic manufacturing, biosimilar development, and clinical trial capacity, although reimbursement depth and specialty access vary significantly. G7 markets remain central to premium innovation, regulatory influence, guideline adoption, and launch sequencing, supported by mature rheumatology networks and established safety monitoring. NATO members overlap substantially with advanced regulatory systems, resilient pharmaceutical supply-chain priorities, and coordinated public health preparedness, which can influence procurement security for immunology and rheumatology medicines.

Key Country Insights in Rheumatology Therapeutics

The United States remains the leading high-value environment for rheumatology therapeutics due to high specialty drug utilization, broad biologic and targeted therapy availability, and intensive payer negotiation. Canada combines strong guideline-based care with provincial reimbursement processes and growing biosimilar policy adoption. Mexico and Brazil are expanding biologic and biosimilar access, although public-sector procurement, private insurance penetration, and affordability shape uptake. The United Kingdom, Germany, France, Italy, and Spain remain core European markets, with Germany often supporting early launch access, the United Kingdom emphasizing cost-effectiveness through health technology assessment, and France, Italy, and Spain balancing clinical need with national and regional reimbursement controls.

Russia continues to develop domestic biologic and biosimilar capacity despite geopolitical and supply-chain pressures. China is scaling local innovation, centralized procurement mechanisms, regulatory modernization, and specialty access, while India’s market is driven by affordability, branded generics, biosimilars, and high out-of-pocket sensitivity. Japan has sophisticated regulatory standards, an aging population, and strong clinical guideline adoption. Australia combines high clinical standards with structured reimbursement assessment, and South Korea serves both as an advanced treatment market and a major biosimilar manufacturing and development hub, supported by strong biopharmaceutical infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value, not only incremental efficacy. Successful strategies should integrate head-to-head evidence where feasible, durable remission data, steroid-sparing outcomes, radiographic progression control, patient-reported outcomes, functional improvement, and safety evidence in populations with cardiovascular, infectious, renal, hepatic, pulmonary, and metabolic comorbidities.

Commercial teams should prepare for biosimilar-driven price pressure by strengthening lifecycle management, companion diagnostics, patient support, real-world evidence generation, clinician education, and access partnerships. R&D leaders should invest in biomarkers, adaptive trials, decentralized monitoring, and AI-enabled response prediction while maintaining rigorous validation, regulatory alignment, and post-market surveillance across diverse patient populations.

Research Methodology

This executive summary is built from a secondary research framework that prioritizes verified public sources, including global health agencies, regulatory authorities, peer-reviewed literature, clinical trial registries, treatment guidelines, pharmacovigilance databases, and health technology assessment publications. Disease burden, therapeutic class evolution, access trends, safety considerations, and regional adoption dynamics were assessed using triangulated evidence rather than single-source interpretation.

The methodology emphasizes market relevance for decision-makers by combining epidemiology, product class analysis, regulatory context, reimbursement dynamics, pipeline direction, prescribing patterns, and real-world implementation factors. Insights are synthesized to support strategic planning across manufacturers, investors, distributors, healthcare providers, payers, and policy stakeholders in rheumatology therapeutics without relying on market sizing, market share, or forecasting assumptions.

Conclusion

Rheumatology therapeutics is entering a more competitive and evidence-driven phase, defined by targeted mechanisms, biosimilar expansion, AI-enabled decision support, and greater demand for measurable patient outcomes. The strongest opportunities will emerge where clinical differentiation aligns with payer affordability, physician confidence, safety transparency, and practical access.

Organizations that combine scientific innovation with real-world evidence, pharmacovigilance strength, patient-centered support, and region-specific access models will be best positioned to advance care. As autoimmune and musculoskeletal disease burdens rise globally, the rheumatology therapeutics landscape will reward therapies that improve remission, function, adherence, treatment persistence, and long-term quality of life.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Rheumatology Therapeutics Market, by Therapeutic Class
7.1. Introduction
7.2. Conventional DMARDs
7.2.1. Hydroxychloroquine
7.2.2. Leflunomide
7.2.3. Methotrexate
7.2.4. Sulfasalazine
7.3. IL-6 Inhibitors
7.4. JAK Inhibitors
7.5. TNF Inhibitors
8. Rheumatology Therapeutics Market, by Molecule Type
8.1. Introduction
8.2. Biologics
8.3. Biosimilars
8.4. Small Molecules
9. Rheumatology Therapeutics Market, by Indication
9.1. Introduction
9.2. Ankylosing Spondylitis
9.3. Gout
9.4. Psoriatic Arthritis
9.5. Rheumatoid Arthritis
9.6. Systemic Lupus Erythematosus
10. Rheumatology Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Rheumatology Therapeutics Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Pediatric
12. Rheumatology Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Rheumatology Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Rheumatology Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Rheumatology Therapeutics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Aclaris Therapeutics, Inc.
17.3. Almirall, S.A.
17.4. Amgen Inc.
17.5. Astellas Pharma Inc.
17.6. AstraZeneca PLC
17.7. Bio-Thera Solutions, Ltd.
17.8. Bristol-Myers Squibb Company
17.9. Chemomab Therapeutics Ltd.
17.10. Dr. Reddy's Laboratories Ltd.
17.11. Eli Lilly and Company
17.12. F. Hoffmann-La Roche Ltd.
17.13. Galapagos NV
17.14. Gilead Sciences, Inc.
17.15. GlaxoSmithKline plc
17.16. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
17.17. Johnson & Johnson services Inc.
17.18. Mallinckrodt Pharmaceuticals plc
17.19. Novartis AG
17.20. Pfizer Inc.
17.21. Sanofi S.A.
17.22. Sun Pharmaceutical Industries Ltd.
17.23. Taisho Pharmaceutical Holdings
17.24. Takeda Pharmaceutical Company Limited
17.25. Teva Pharmaceutical Industries Ltd.
17.26. UCB S.A.
List of Figures
FIGURE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONVENTIONAL DMARDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONVENTIONAL DMARDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONVENTIONAL DMARDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HYDROXYCHLOROQUINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HYDROXYCHLOROQUINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HYDROXYCHLOROQUINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL LEFLUNOMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LEFLUNOMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LEFLUNOMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL METHOTREXATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL METHOTREXATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL METHOTREXATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SULFASALAZINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SULFASALAZINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SULFASALAZINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IL-6 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IL-6 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IL-6 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL GOUT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL GOUT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL GOUT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 103. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 105. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 106. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 107. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 110. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 116. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 121. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 122. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 123. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 124. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 126. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 130. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 131. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 132. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 133. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 134. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 135. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 138. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 139. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 140. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 141. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 143. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 154. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 155. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 156. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 157. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 159. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 162. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 163. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 164. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 165. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 167. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 170. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 171. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 172. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 173. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 183. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 184. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 185. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 186. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 187. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 188. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 189. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 190. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 192. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 193. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 195. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 196. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 197. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 198. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 200. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 203. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 204. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 205. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 208. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 211. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 212. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 213. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 216. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 217. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 219. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 220. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 222. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 223. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 224. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 227. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 228. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 229. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 230. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 232. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 235. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 236. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 237. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 238. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 240. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 243. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 244. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 245. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 246. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 251. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 252. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 253. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 254. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 256. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 259. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 260. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 261. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 262. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 264. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 267. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 268. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 269. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 270. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 271. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 272. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 275. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 276. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 277. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 278. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 280. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 288. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 293. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 294. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 297. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 298. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Almirall, S.A.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bio-Thera Solutions, Ltd.
  • Bristol-Myers Squibb Company
  • Chemomab Therapeutics Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson services Inc.
  • Mallinckrodt Pharmaceuticals plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Taisho Pharmaceutical Holdings
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 37.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 55.88 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Rheumatology Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Rheumatology Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Rheumatology Therapeutics Market Report 2026 - Product Image

Rheumatology Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 182 Pages
  • Global
From
Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2026-2034 - Product Image

Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2026-2034

  • Report
  • 149 Pages
  • Global
From

About the Market

The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.